<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00815347</url>
  </required_header>
  <id_info>
    <org_study_id>08-287-1</org_study_id>
    <secondary_id>001</secondary_id>
    <nct_id>NCT00815347</nct_id>
  </id_info>
  <brief_title>Bosentan for Poorly Controlled Asthma</brief_title>
  <official_title>The Effect of the ET-1 Receptor Antagonist, Bosentan on Patients With Poorly Controlled Asthma-A 17 Week, Double-blind, Placebo Controlled Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UConn Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UConn Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: The endothelin-1 receptor antagonist, bosentan when added to the treatment of
      asthma patients who are symptomatic despite the use of controller therapy will improve asthma
      symptoms and physiology.

      Twenty patients with a diagnosis of asthma, between the ages of 21 and 70 who are symptomatic
      despite the use of at least one controller medication will be randomized to either placebo or
      active medication for an 8 week period (initial 4 weeks is at 1/2 of final dose as per
      package insert and FDA approval). Measures of lung function and symptoms will be recorded.
      Patients will then cross over, so that patients initially on placebo will receive active drug
      for 8 weeks and those initially on active drug will receive placebo. The same endpoints will
      be measured. The acute bronchodilator effects of the drug will also be tested on the first
      day of therapy at the full therapeutic dose.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty in recruitment.
  </why_stopped>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in FEV1</measure>
    <time_frame>1, 2, 4 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Flow</measure>
    <time_frame>last 7 days of each dosing period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom Scores</measure>
    <time_frame>Last 7 days of each dosing period</time_frame>
    <description>Symptom score could range from a minimum of 7 (no symptoms) to 35 (severe symptoms)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1</measure>
    <time_frame>end of dosing period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Beta-agonist</measure>
    <time_frame>end of each dosing period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Test Questionnaire</measure>
    <time_frame>end of each dosing period</time_frame>
    <description>Patient reported outcome minimum 5 (no symptoms) maximum 25 (severe symptoms)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Requirement for Escalation of Controller Medication.</measure>
    <time_frame>17 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Requirement for Urgent Medical Care for Asthma.</measure>
    <time_frame>17 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Ability to Taper Systemic Steroids Among Those Patients Who Are on Systemic Steroids at Study Entry.</measure>
    <time_frame>17 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1 Crossover</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bosentan</intervention_name>
    <description>Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.</description>
    <arm_group_label>1 Crossover</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.</description>
    <arm_group_label>1 Crossover</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of asthma, maintained on a minimum of 1 anti-inflammatory/controller and
             daily long acting B-agonist therapy with inadequate control of symptoms. (Defined as
             symptoms including wheezing, chest tightness or shortness of breath occurring at least
             3 times a week or requiring use of &quot;rescue&quot; short-acting B-agonist at least 3 times a
             week).

          -  FEV1 less than 80% of predicted and greater than 40% at screening visit.

          -  A minimum of 12% reversibility of FEV1 after albuterol on screening visit or
             previously documented during the prior two years.

          -  Women of childbearing potential must use 2 non-hormonal methods of birth control (2
             methods between the subject and her partner) while on the study and for 1 month after
             the last dose of study medication.

          -  Male subjects must use two non hormonal methods of birth control (2 methods between
             the subject and his partner) while on the study and for 1 month after the last dose of
             study medication.

        Exclusion Criteria:

          -  History of liver disease, clinically significant cardiac disease, renal disease or
             pulmonary disease other than asthma. Patients with clinically significant laboratory
             abnormalities of LFTs/bilirubin (AST/ALT, TBili, alkaline phosphatase) and clinically
             significant anemia will be excluded. Clinically significant anemia will be defined as
             any anemia resulting in serum Hgb more than 1 gm/dl below the LLN, Patients with
             isolated minimal elevations of bilirubin (eg. as occurs in Gilbert's disease) or
             minimal elevations in transaminases (less than 1.2 x ULN) without a history of liver
             disease, risk factors for liver disease or symptoms of liver disease may still be
             included in the study at the investigator's discretion, but will have LFT testing at
             each study visit.)

          -  Cigarette history of &gt;10 pack years.

          -  Predicted inability to adhere to medication regimen or documentation requirements of
             the study (symptom and medication diaries).

          -  Respiratory infection during 30 days preceding screening visit.

          -  Requirement for change in scheduled asthma medication use, including oral steroid dose
             change, or acute medical care for asthma during the 30 days preceding screening visit.

          -  Predicted inability to safely refrain from B-agonist use for the required amount of
             time on study visit days.

          -  Use of tiotropium

          -  Pregnancy, breast feeding or the use of hormonal methods of birth control as the only
             means of birth control during the study.

          -  Use of potent CYP3A4 and CYP2C9 inhibitors, including, but not limited to azole
             antifungals, amiodarone, glyburide, warfarin, cyclosporine, ritonavir, other
             medications potentially toxic to the liver or bone marrow.

          -  Use of any illegal drugs or alcohol abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark L Metersky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UConn Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030-2810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2008</study_first_submitted>
  <study_first_submitted_qc>December 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2008</study_first_posted>
  <results_first_submitted>June 16, 2012</results_first_submitted>
  <results_first_submitted_qc>September 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 1, 2012</results_first_posted>
  <last_update_submitted>September 28, 2012</last_update_submitted>
  <last_update_submitted_qc>September 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UConn Health</investigator_affiliation>
    <investigator_full_name>Mark Metersky</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in FEV1</title>
        <time_frame>1, 2, 4 hours after dosing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Bosentan</title>
          </group>
        </group_list>
        <measure>
          <title>Change in FEV1</title>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour FEV1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50">Confidence interval not evaluable due to small number of participants</measurement>
                    <measurement group_id="O2" value="1.57">Confidence interval not evaluable due to small number of participants</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hour FEV1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53">Confidence interval not evaluable due to small number of participants</measurement>
                    <measurement group_id="O2" value="1.57">Confidence interval not evaluable due to small number of participants</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hour FEV1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50">Confidence interval not evaluable due to small number of participants</measurement>
                    <measurement group_id="O2" value="1.51">Confidence interval not evaluable due to small number of participants</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak Flow</title>
        <time_frame>last 7 days of each dosing period</time_frame>
        <population>Data not analyzed, study terminated early</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Bosentan</title>
          </group>
        </group_list>
        <measure>
          <title>Peak Flow</title>
          <population>Data not analyzed, study terminated early</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Symptom Scores</title>
        <description>Symptom score could range from a minimum of 7 (no symptoms) to 35 (severe symptoms)</description>
        <time_frame>Last 7 days of each dosing period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Bosentan</title>
          </group>
        </group_list>
        <measure>
          <title>Symptom Scores</title>
          <description>Symptom score could range from a minimum of 7 (no symptoms) to 35 (severe symptoms)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7" spread="7.6"/>
                    <measurement group_id="O2" value="20.1" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1</title>
        <time_frame>end of dosing period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Bosentan</title>
          </group>
        </group_list>
        <measure>
          <title>FEV1</title>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread="0.4"/>
                    <measurement group_id="O2" value="1.49" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Beta-agonist</title>
        <time_frame>end of each dosing period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Bosentan</title>
          </group>
        </group_list>
        <measure>
          <title>Rescue Beta-agonist</title>
          <units>puffs of rescue inhaler</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6" spread="19.2"/>
                    <measurement group_id="O2" value="36.3" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Requirement for Escalation of Controller Medication.</title>
        <time_frame>17 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Requirement for Urgent Medical Care for Asthma.</title>
        <time_frame>17 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Ability to Taper Systemic Steroids Among Those Patients Who Are on Systemic Steroids at Study Entry.</title>
        <time_frame>17 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Control Test Questionnaire</title>
        <description>Patient reported outcome minimum 5 (no symptoms) maximum 25 (severe symptoms)</description>
        <time_frame>end of each dosing period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Bosentan</title>
          </group>
        </group_list>
        <measure>
          <title>Asthma Control Test Questionnaire</title>
          <description>Patient reported outcome minimum 5 (no symptoms) maximum 25 (severe symptoms)</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" spread="5.0"/>
                    <measurement group_id="O2" value="13.1" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>17 weeks</time_frame>
      <desc>Non-Serious Adverse Events were not Analyzed, Terminated Study</desc>
      <group_list>
        <group group_id="E1">
          <title>Bosentan</title>
          <description>Bosentan 62.5mg orally, twice a day for four weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo orally, twice a day for four weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal liver function blood tests</sub_title>
                <description>Very elevated liver function tests, while receiving placebo</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>MArk Metersky, MD</name_or_title>
      <organization>University of Connecticut Health Center</organization>
      <phone>860-679-3582</phone>
      <email>metersky@nso.uchc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

